Meta-analysis evaluating adjunctive metformin in treatment of AP-associated hyperprolactinemia.Results: The metformin group exhibited a significantly lower serum prolactin level at the endpoint. The rate of menstruation resumption in patients with menstrual disturbances was notably higher at 66.7% in the metformin group compared to 4.8% in the control group. Adverse drug reactions and all-cause discontinuation were similar between the metformin and control groups.Main conclusion: Adjunctive metformin is effective and safe for reducing hyperprolactinemia and prolactin-related symptoms. Here, PRL is linked to hyperprolactinemia.